The USA is the only significant user of chimpanzees in biomedical research in the world, since many countries have banned or limited the practice due to substantial ethical, economic and scientific concerns. Advocates of chimpanzee use cite hepatitis C research as a major reason for its necessity and continuation, in spite of supporting evidence that is scant and often anecdotal. This paper examines the scientific and ethical issues surrounding chimpanzee hepatitis C research, and concludes that claims of the necessity of chimpanzees in historical and future hepatitis C research are exaggerated and unjustifiable, respectively. The chimpanzee model has several major scientific, ethical, economic and practical caveats. It has made a relatively negligible contribution to knowledge of, and tangible progress against, the hepatitis C virus compared to non-chimpanzee research, and must be considered scientifically redundant, given the array of alternative methods of inquiry now available. The continuation of chimpanzee use in hepatitis C research adversely affects scientific progress, as well as chimpanzees and humans in need of treatment. Unfounded claims of its necessity should not discourage changes in public policy regarding the use of chimpanzees in US laboratories.
BradshawG.A., CapaldoT., LindnerL. & GrowG. (2008). Building an inner sanctuary: Complex PTSD in chimpanzees. Journal of Trauma & Dissociation9, 9–34.
3.
BradshawG.A., CapaldoT., LindnerL. & GrowG. (2009). Developmental context effects on bi-cultural post-trauma self repair in chimpanzees. Developmental Psychology45, 1376–1388.
4.
SauerU.G. (2000). Reasons for not using primates in research. [In German] ALTEX17, 217–220.
5.
ThewM. (2002). Are results of primate research worth the suffering it causes?Nature, London418, 273.
6.
BaileyJ. (2008). An assessment of the role of chimpanzees in AIDS vaccine research. ATLA36, 381–428.
7.
BaileyJ., BalcombeJ. & CapaldoT. (2007). Chimpanzee Research: An Examination of Its Contribution to Biomedical Knowledge and Efficacy in Combating Human Diseases, 47pp. Boston, MA, USA: New England Anti-Vivisection Society (Project R&R). Available at: http://www.releasechimps.org/pdfs/chimp-efficacy-paper-main.pdf (Accessed 17.08. 10).
8.
KnightA. (2007). The poor contribution of chimpanzee experiments to biomedical progress. Journal of Applied Animal Welfare Science10, 281–308.
9.
de KokW. (2002). Dutch Lab Chimps to be Retired. Summerville, SC, USA: International Primate Protection League. Available at: http://www.ippl.org/2002-dutch-chimps.php (Accessed 20.07.10).
10.
VermijP. (2003). Europe's last research chimps to retire. Nature Medicine9, 981.
CohenJ. (2007). Biomedical research. The endangered lab chimp. Science, New York315, 450–452.
15.
VandeBergJ.L. & ZolaS.M. (2005). A unique biomedical resource at risk. Nature, London437, 30–32.
16.
BaileyJ. (2009). An examination of the use of chimpanzees in human cancer research. ATLA37, 399–416.
17.
BaileyJ. (2010). An assessment of the use of chimpanzees in hepatitis C research past, present and future: 2. Alternative replacement methods. ATLA [In press].
18.
SeeffL.B. (2009). The history of the “natural history” of hepatitis C (1968–2009). Liver International29, Suppl. 1, 89–99.
19.
FeinstoneS.M., KapikianA.Z., PurcellR.H., AlterH.J. & HollandP.V. (1975). Transfusion-associated hepatitis not due to viral hepatitis type A or B. New England Journal of Medicine292, 767–770.
20.
ChooQ.L., KuoG., WeinerA.J., OverbyL.R., BradleyD.W. & HoughtonM. (1989). Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science, New York244, 359–362.
21.
AlterH.J., PurcellR.H., ShihJ.W., MelpolderJ.C., HoughtonM., ChooQ.L. & KuoG. (1989). Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. New England Journal of Medicine321, 1494–1500.
22.
KuoG., ChooQ.L., AlterH.J., GitnickG.L., RedekerA.G., PurcellR.H., MiyamuraT., DienstagJ.L., AlterM.J., StevensC.E., TegtmeierG.E., BoninoF., ColomboM., LeeW-S., KuoC., BergerK., ShusterJ.R., OverbyL.R., BradleyD.W. & HoughtonM. (1989). An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science, New York244, 362–364.
23.
GottweinJ.M. & BukhJ. (2008). Cutting the Gordian knot-development and biological relevance of hepatitis C virus cell culture systems. Advances in Virus Research71, 51–133.
24.
MarcellinP. (2009). Hepatitis B and hepatitis C in 2009. Liver International29, Suppl. 1, 1–8.
25.
SorianoV., MadejonA., VispoE., LabargaP., Garcia-SamaniegoJ., Martin-CarboneroL., SheldonJ., BottecchiaM., TumaP. & BarreiroP. (2008). Emerging drugs for hepatitis C. Expert Opinion on Emerging Drugs13, 1–19.
26.
ShepardC.W., FinelliL. & AlterM.J. (2005). Global epidemiology of hepatitis C virus infection. Lancet Infectious Diseases5, 558–567.
27.
BrownR.S. (2005). Hepatitis C and liver transplantation. Nature, London436, 973–978.
28.
AgnelloV. & De RosaF.G. (2004). Extrahepatic disease manifestations of HCV infection: Some current issues. Journal of Hepatology40, 341–352.
29.
LeratH., BerbyF., TrabaudM.A., VidalinO., MajorM., TrepoC. & InchauspéG. (1996). Specific detection of hepatitis C virus minus strand RNA in hematopoietic cells. Journal of Clinical Investigation97, 845–851.
30.
BarriaM.I., Vera-OtarolaJ., LeonU., VollrathV., MarsacD., RiquelmeA., Lopez-LastraM. & SozaA. (2008). Influence of extrahepatic viral infection on the natural history of hepatitis C. Annals of Hepatology7, 136–143.
31.
DienstagJ.L. & McHutchisonJ.G. (2006). American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology130, 231–264; quiz 214–217.
32.
BrassV., MoradpourD. & BlumH.E. (2007). Hepatitis C virus infection: In vivo and in vitro models. Journal of Viral Hepatitis14, Suppl. 1, 64–67.
33.
WaltersK-A. & KatzeM.G. (2009). Using high-throughput genomics to study hepatitis C: What determines the outcome of infection?Antiviral Research81, 198–208.
34.
PoynardT., BedossaP. & OpolonP. (1997). Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet349, 825–832.
35.
LauerG.M. & WalkerB.D. (2001). Hepatitis C virus infection. New England Journal of Medicine345, 41–52.
36.
AlbertM.L., DecalfJ. & PolS. (2008). Plasmacytoid dendritic cells move down on the list of suspects: In search of the immune pathogenesis of chronic hepatitis C. Journal of Hepatology49, 1069–1078.
37.
KimJ.W. & WangX.W. (2003). Gene expression profiling of preneoplastic liver disease and liver cancer: A new era for improved early detection and treatment of these deadly diseases?Carcinogenesis24, 363–369.
38.
SimmondsP. (2004). Genetic diversity and evolution of hepatitis C virus — 15 years on. Journal of General Virology85, 3173–3188.
39.
Anon. (2002). National Institutes of Health consensus development conference statement: Management of hepatitis C. Hepatology36, Suppl. 1, S3–S20.
40.
DhumeauxD., MarcellinP. & LereboursE. (2003). Treatment of hepatitis C. The 2002 French consensus. Gut52, 1784–1787.
41.
FriedM.W. & HadziyannisS.J. (2004). Treatment of chronic hepatitis C infection with peginterferons plus ribavirin. Seminars in Liver Disease24, Suppl. 2, 47–54.
42.
MannsM.P., FosterG.R., RockstrohJ.K., ZeuzemS., ZoulimF. & HoughtonM. (2007). The way forward in HCV treatment — finding the right path. Nature Reviews Drug Discovery6, 991–1000.
43.
HadziyannisS.J., SetteH.J., MorganT.R., BalanV., DiagoM., MarcellinP., RamadoriG., BodenheimerH.J., BernsteinD., RizzettoM., ZeuzemS., PockrosP.J., LinA. & AckrillA.M. (2004). Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Annals of Internal Medicine140, 346–355.
44.
FriedM.W., ShiffmanM.L., ReddyK.R., SmithC., MarinosG., GoncalesF.L.J., HaussingerD., DiagoM., CarosiG., DhumeauxD., CraxiA., LinA., HoffmanJ. & YuJ. (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine347, 975–982.
45.
MannsM.P., McHutchisonJ.G., GordonS.C., RustgiV.K., ShiffmanM., ReindollarR., GoodmanZ.D., KouryK., LingM. & AlbrechtJ.K. (2001). Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet358, 958–965.
46.
McHutchisonJ.G., GordonS.C., SchiffE.R., ShiffmanM.L., LeeW.M., RustgiV.K., GoodmanZ.D., LingM.H., CortS. & AlbrechtJ.K. (1998). Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. New England Journal of Medicine339, 1485–1492.
47.
MuirA.J., BornsteinJ.D. & KillenbergP.G. (2004). Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. New England Journal of Medicine350, 2265–2271.
48.
MarcellinP., BoyerN., GervaisA., MartinotM., PouteauM., CastelnauC., KilaniA., AreiasJ., AuperinA., BenhamouJ.P., DegottC. & ErlingerS. (1997). Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Annals of Internal Medicine127, 875–881.
49.
MaylinS., Martinot-PeignouxM., MoucariR., BoyerN., RipaultM.P., Cazals-HatemD., GiuilyN., CastelnauC., CardosoA.C., AsselahT., FerayC., Nicolas-ChanoineM.H., BedossaP. & MarcellinP. (2008). Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology135, 821–829.
50.
AsselahT., BenhamouY. & MarcellinP. (2009). Protease and polymerase inhibitors for the treatment of hepatitis C. Liver International29, Suppl. 1, 57–67.
51.
SimmondsP., BukhJ., CombetC., DeleageG., EnomotoN., FeinstoneS., HalfonP., InchauspéG., KuikenC., MaertensG., MizokamiM., MurphyD.G., OkamotoH., PawlotskyJ.M., PeninF., SablonE., Shin-IT., StuyverL.J., ThielH.J., ViazovS., WeinerA.J. & WidellA. (2005). Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology42, 962–973.
52.
HoughtonM. & AbrignaniS. (2005). Prospects for a vaccine against the hepatitis C virus. Nature, London436, 961–966.
53.
Falck-YtterY., KaleH., MullenK.D., SarbahS.A., SorescuL. & McCulloughA.J. (2002). Surprisingly small effect of antiviral treatment in patients with hepatitis C. Annals of Internal Medicine136, 288–292.
54.
De FrancescoR. & MigliaccioG. (2005). Challenges and successes in developing new therapies for hepatitis C. Nature, London436, 953–960.
55.
FeldJ.J. & HoofnagleJ.H. (2005). Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature, London436, 967–972.
56.
MannsM.P., WedemeyerH. & CornbergM. (2006). Treating viral hepatitis C: Efficacy, side effects, and complications. Gut55, 1350–1359.
57.
BowenD.G. & WalkerC.M. (2005). Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature, London436, 946–952.
58.
LangK. & WeinerD.B. (2008). Immunotherapy for HCV infection: Next steps. Expert Review of Vaccines7, 915–923.
59.
BettauerR.H. (2010). Chimpanzees in hepatitis C virus research: 1998–2007. Journal of Medical Primatology39, 9–23.
60.
PrinceA.M., BrotmanB., LeeD.H., PfahlerW., TricocheN., AndrusL. & ShataM.T. (2005). Protection against chronic hepatitis C virus infection after rechallenge with homologous, but not heterologous, genotypes in a chimpanzee model. Journal of Infectious Diseases192, 1701–1709.
61.
SakaiA., TakikawaS., ThimmeR., MeunierJ.C., SpangenbergH.C., GovindarajanS., FarciP., EmersonS.U., ChisariF.V., PurcellR.H. & BukhJ. (2007). In vivo study of the HC-TN strain of hepatitis C virus recovered from a patient with fulminant hepatitis: RNA transcripts of a molecular clone (pHC-TN) are infectious in chimpanzees but not in Huh7.5 cells. Journal of Virology81, 7208–7219.
62.
YanagiM., St ClaireM., ShapiroM., EmersonS.U., PurcellR.H. & BukhJ. (1998). Transcripts of a chimeric cDNA clone of hepatitis C virus genotype 1b are infectious in vivo. Virology244, 161–172.
BiggerC.B., BraskyK.M. & LanfordR.E. (2001). DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. Journal of Virology75, 7059–7066.
66.
BukhJ., PietschmannT., LohmannV., KriegerN., FaulkK., EngleR.E., GovindarajanS., ShapiroM., St ClaireM. & BartenschlagerR. (2002). Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees. Proceedings of the National Academy of Sciences of the USA99, 14,416–14,421.
67.
SakaiA., St ClaireM., FaulkK., GovindarajanS., EmersonS.U., PurcellR.H. & BukhJ. (2003). The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences. Proceedings of the National Academy of Sciences of the USA100, 11,646–11,651.
68.
ShimizuY.K., IgarashiH., KiyoharaT., ShapiroM., WongD.C., PurcellR.H. & YoshikuraH. (1998). Infection of a chimpanzee with hepatitis C virus grown in cell culture. Journal of General Virology79, 1383–1386.
69.
SuA.I., PezackiJ.P., WodickaL., BrideauA.D., SupekovaL., ThimmeR., WielandS., BukhJ., PurcellR.H., SchultzP.G. & ChisariF.V. (2002). Genomic analysis of the host response to hepatitis C virus infection. Proceedings of the National Academy of Sciences of the USA99, 15,669–15,674.
70.
MaillardP., KrawczynskiK., NitkiewiczJ., BronnertC., SidorkiewiczM., GounonP., DubuissonJ., FaureG., CrainicR. & BudkowskaA. (2001). Nonenveloped nucleocapsids of hepatitis C virus in the serum of infected patients. Journal of Virology75, 8240–8250.
71.
CaldwellS.H. (2001). Controlling pain in liver biopsy, or “we will probably need to repeat the biopsy in a year or two to assess the response”. American Journal of Gastroenterology96, 1327–1329.
72.
MajorM.E., MihalikK., PuigM., RehermannB., NascimbeniM., RiceC.M. & FeinstoneS.M. (2002). Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. Journal of Virology76, 6586–6595.
73.
YanagiM., PurcellR.H., EmersonS.U. & BukhJ. (1999). Hepatitis C virus: An infectious molecular clone of a second major genotype (2a) and lack of viability of intertypic 1a and 2a chimeras. Virology262, 250–263.
74.
NascimbeniM., MizukoshiE., BosmannM., MajorM.E., MihalikK., RiceC.M., FeinstoneS.M. & RehermannB. (2003). Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. Journal of Virology77, 4781–4793.
75.
KolykhalovA.A., MihalikK., FeinstoneS.M. & RiceC.M. (2000). Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3’ nontranslated region are essential for virus replication in vivo. Journal of Virology74, 2046–2051.
76.
EsumiM., RikihisaT., NishimuraS., GotoJ., MizunoK., ZhouY.H. & ShikataT. (1999). Experimental vaccine activities of recombinant E1 and E2 glycoproteins and hypervariable region 1 peptides of hepatitis C virus in chimpanzees. Archives of Virology144, 973–980.
PuigM., MajorM.E., MihalikK. & FeinstoneS.M. (2004). Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection. Vaccine22, 991–1000.
TaborE., GeretyR.J., DruckerJ.A., SeeffL.B., HoofnagleJ.H., JacksonD.R., AprilM., BarkerL.F. & Pineda-TamondongG. (1978). Trans mission of non-A, non-B hepatitis from man to chimpanzee. Lancet312 (8062), 4 March, 463–466.
81.
HeL.F., AllingD., PopkinT., ShapiroM., AlterH.J. & PurcellR.H. (1987). Determining the size of non-A, non-B hepatitis virus by filtration. Journal of Infectious Diseases156, 636–640.
82.
FeinstoneS.M., MihalikK.B., KamimuraT., AlterH.J., LondonW.T. & PurcellR.H. (1983). Inactivation of hepatitis B virus and non-A, non-B hepatitis by chloroform. Infection & Immunity41, 816–821.
83.
FarciP. (2002). ChooQL, KuoG, WeinerAJ, OverbyLR, BradleyDW, HoughtonM.Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome [Science 1989; 244:359–362]. Journal of Hepatology36, 582–585.
84.
KolykhalovA.A., AgapovE.V., BlightK.J., MihalikK., FeinstoneS.M. & RiceC.M. (1997). Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science, New York277, 570–574.
85.
YanagiM., PurcellR.H., EmersonS.U. & BukhJ. (1997). Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proceedings of the National Academy of Sciences of the USA94, 8738–8743.
86.
BukhJ. (2004). A critical role for the chimpanzee model in the study of hepatitis C. Hepatology39, 1469–1475.
87.
LanfordR.E., BiggerC., BassettS. & KlimpelG. (2001). The chimpanzee model of hepatitis C virus infections. ILAR Journal42, 117–126.
88.
FarciP., AlterH.J., GovindarajanS., WongD.C., EngleR., LesniewskiR.R., MushahwarI.K., DesaiS.M., MillerR.H., OgataN. & PurcellR.H. (1992). Lack of protective immunity against reinfection with hepatitis C virus. Science, New York258, 135–140.
89.
PrinceA.M., BrotmanB., HuimaT., PascualD., JafferyM. & InchauspéG. (1992). Immunity in hepatitis C infection. Journal of Infectious Diseases165, 438–443.
90.
BukhJ., FornsX., EmersonS.U. & PurcellR.H. (2001). Studies of hepatitis C virus in chimpanzees and their importance for vaccine development. Intervirology44, 132–142.
91.
AkariH., IwasakiY., YoshidaT. & IijimaS. (2009). Non-human primate surrogate model of hepatitis C virus infection. Microbiology & Immunology53, 53–57.
92.
InchauspéG. & MichelM.L. (2007). Vaccines and immunotherapies against hepatitis B and hepatitis C viruses. Journal of Viral Hepatitis14, Suppl. 1, 97–103.
CarrollS.S., LudmererS., HandtL., KoeplingerK., ZhangN.R., GrahamD., DaviesM-E., MacCossM., HazudaD. & OlsenD.B. (2009). Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees. Antimicrobial Agents & Chemotherapy53, 926–934.
95.
MajorM.E. & FeinstoneS.M. (2000). Characterization of hepatitis C virus infectious clones in chimpanzees: Long-term studies. Current Topics in Microbiology & Immunology242, 279–298.
96.
BassettS.E., BraskyK.M. & LanfordR.E. (1998). Analysis of hepatitis C virus-inoculated chimpanzees reveals unexpected clinical profiles. Journal of Virology72, 2589–2599.
97.
BassettS.E., ThomasD.L., BraskyK.M. & LanfordR.E. (1999). Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees. Journal of Virology73, 1118–1126.
98.
PrinceA.M., BrotmanB., LeeD.H., RenL., MooreB.S. & ScheffelJ.W. (1999). Significance of the anti-E2 response in self-limited and chronic hepatitis C virus infections in chimpanzees and in humans. Journal of Infectious Diseases180, 987–991.
99.
RayS.C., MaoQ., LanfordR.E., BassettS., LaeyendeckerO., WangY.M. & ThomasD.L. (2000). Hypervariable region 1 sequence stability during hepatitis C virus replication in chimpanzees. Journal of Virology74, 3058–3066.
100.
ZanettiA.R., TanziE., PaccagniniS., PrincipiN., PizzocoloG., CaccamoM.L., D'AmicoE., CambieG. & VecchiL. (1995). Mother-to-infant transmission of hepatitis C virus. Lombardy Study Group on Vertical HCV Transmission. Lancet345, 289–291.
101.
HoughtonM. (2009). Discovery of the hepatitis C virus. Liver International29, Suppl. 1, 82–88.
102.
AlterH.J. & HoughtonM. (2000). Clinical Medical Research Award. Hepatitis C virus and eliminating post-transfusion hepatitis. Nature Medicine6, 1082–1086.
103.
BlumbergB.S., AlterH.J. & VisnichS. (1965). A “new” antigen in leukemia sera. JAMA191, 541–546.
104.
AlterH.J., HollandP.V., MorrowA.G., PurcellR.H., FeinstoneS.M. & MoritsuguY. (1975). Clinical and serological analysis of transfusion-associated hepatitis. Lancet306 (7940), 8 November, 838–841.
BermanM., AlterH.J., IshakK.G., PurcellR.H. & JonesE.A. (1979). The chronic sequelae of non-A, non-B hepatitis. Annals of Internal Medicine91, 1–6.
107.
AachR.D., SzmunessW., MosleyJ.W., HollingerF.B., KahnR.A., StevensC.E., EdwardsV.M. & WerchJ. (1981). Serum alanine amino-transferase of donors in relation to the risk of non-A, non-B hepatitis in recipients: The transfusion-transmitted viruses study. New England Journal of Medicine304, 989–994.
108.
AlterM.J., GeretyR.J., SmallwoodL.A., SamplinerR.E., TaborE., DeinhardtF., FrosnerG. & MatanoskiG.M. (1982). Sporadic non-A, non-B hepatitis: Frequency and epidemiology in an urban U.S. population. Journal of Infectious Diseases145, 886–893.
109.
AlterH.J. (1989). Chronic sequences of non-A, non-B hepatitis. In Current Perspectives in Hepatology (ed. SeeffL.B. & LewisJ.H.), pp. 83–97. New York, NY, USA: Plenum Medical.
110.
GilliamJ.H.3rd, GeisingerK.R. & RichterJ.E. (1984). Primary hepatocellular carcinoma after chronic non-A, non-B post-transfusion hepatitis. Annals of Internal Medicine101, 794–795.
111.
MullisK.B. & FaloonaF.A. (1987). Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. Methods in Enzymology155, 335–350.
112.
ColomboM., KuoG., ChooQ.L., DonatoM.F., Del NinnoE., TommasiniM.A., DioguardiN. & HoughtonM. (1989). Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet334 (8670), 28 October, 1006–1008.
113.
MoritaT., HadaH., KoideN., ShirahaH., ShinjiT., NakamuraM., UjikeK., WatoM., ShimomuraH. & TsujiT. (1996). Detection of hepatitis C virus RNA in circulating immune complexes by RT-PCR. Hepatogastroenterology43, 582–585.
114.
FujitaN., KaitoM., TakeoM., IwasaM., IkomaJ., WatanabeS. & AdachiY. (2003). Nonimmune complexed HCV RNA titer in serum as a predictor of interferon response in patients with chronic hepatitis C. American Journal of Gastroenterology98, 645–652.
115.
GaleM.J. & BeardM.R. (2001). Molecular clones of hepatitis C virus: Applications to animal models. ILAR Journal42, 139–151.
116.
DuverlieG. & WychowskiC. (2007). Cell culture systems for the hepatitis C virus. World Journal of Gastroenterology13, 2442–2445.
117.
MoormannR.J., van GennipH.G., MiedemaG.K., HulstM.M. & van RijnP.A. (1996). Infectious RNA transcribed from an engineered full-length cDNA template of the genome of a pestivirus. Journal of Virology70, 763–770.
118.
BartenschlagerR. (2006). Hepatitis C virus molecular clones: From cDNA to infectious virus particles in cell culture. Current Opinion in Microbiology9, 416–422.
119.
HigashiY., KakumuS., YoshiokaK., WakitaT., MizokamiM., OhbaK., ItoY., IshikawaT., TakayanagiM. & NagaiY. (1993). Dynamics of genome change in the E2/NS1 region of hepatitis C virus in vivo. Virology197, 659–668.
120.
YagiS., MoriK., TanakaE., MatsumotoA., SunagaF., KiyosawaK. & YamaguchiK. (2005). Identification of novel HCV subgenome replicating persistently in chronic active hepatitis C patients. Journal of Medical Virology77, 399–413.
121.
SheehyP., MullanB., MoreauI., Kenny-WalshE., ShanahanF., ScallanM. & FanningL.J. (2007). In vitro replication models for the hepatitis C virus. Journal of Viral Hepatitis14, 2–10.
122.
YooB.J., SelbyM.J., ChoeJ., SuhB.S., ChoiS.H., JohJ.S., NuovoG.J., LeeH.S., HoughtonM. & HanJ.H. (1995). Transfection of a differentiated human hepatoma cell line (Huh7) with in vitro-transcribed hepatitis C virus (HCV) RNA and establishment of a long-term culture persistently infected with HCV. Journal of Virology69, 32–38.
123.
DashS., HalimA.B., TsujiH., HiramatsuN. & GerberM.A. (1997). Transfection of HepG2 cells with infectious hepatitis C virus genome. American Journal of Pathology151, 363–373.
124.
OkamotoH., OkadaS., SugiyamaY., KuraiK., IizukaH., MachidaA., MiyakawaY. & MayumiM. (1991). Nucleotide sequence of the genomic RNA of hepatitis C virus isolated from a human carrier: Comparison with reported isolates for conserved and divergent regions. Journal of General Virology72, 2697–2704.
125.
TakamizawaA., MoriC., FukeI., ManabeS., MurakamiS., FujitaJ., OnishiE., AndohT., YoshidaI. & OkayamaH. (1991). Structure and organization of the hepatitis C virus genome isolated from human carriers. Journal of Virology65, 1105–1113.
126.
KatoN., HijikataM., OotsuyamaY., NakagawaM., OhkoshiS., SugimuraT. & ShimotohnoK. (1990). Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proceedings of the National Academy of Sciences of the USA87, 9524–9528.
127.
BartenschlagerR. & SparacioS. (2007). Hepatitis C virus molecular clones and their replication capacity in vivo and in cell culture. Virus Research127, 195–207.
128.
BeardM.R., AbellG., HondaM., CarrollA., GartlandM., ClarkeB., SuzukiK., LanfordR., SangarD.V. & LemonS.M. (1999). An infectious molecular clone of a Japanese genotype 1b hepatitis C virus. Hepatology30, 316–324.
129.
LanfordR.E., LeeH., ChavezD., GuerraB. & BraskyK.M. (2001). Infectious cDNA clone of the hepatitis C virus genotype 1 prototype sequence. Journal of General Virology82, 1291–1297.
130.
YanagiM., St ClaireM., EmersonS.U., PurcellR.H. & BukhJ. (1999). In vivo analysis of the 3’ untranslated region of the hepatitis C virus after in vitro mutagenesis of an infectious cDNA clone. Proceedings of the National Academy of Sciences of the USA96, 2291–2295.
131.
MyungJ., KhalapN., KalkeriG., GarryR. & DashS. (2001). Inducible model to study negative strand RNA synthesis and assembly of hepatitis C virus from a full-length cDNA clone. Journal of Virological Methods94, 55–67.
132.
LimS.P., SooH.M., TanY.H., BrennerS., HorstmannH., MacKenzieJ.M., NgM.L., LimS.G. & HongW. (2002). Inducible system in human hepatoma cell lines for hepatitis C virus production. Virology303, 79–99.
133.
MoradpourD., WakitaT., WandsJ.R. & BlumH.E. (1998). Tightly regulated expression of the entire hepatitis C virus structural region in continuous human cell lines. Biochemical & Biophysical Research Communications246, 920–924.
134.
MoradpourD., KaryP., RiceC.M. & BlumH.E. (1998). Continuous human cell lines inducibly expressing hepatitis C virus structural and non-structural proteins. Hepatology28, 192–201.
HuangY., UchiyamaY., FujimuraT., KanamoriH., DoiT., TakamizawaA., HamakuboT. & KodamaT. (2001). A human hepatoma cell line expressing hepatitis C virus nonstructural proteins tightly regulated by tetracycline. Biochemical & Biophysical Research Communications281, 732–740.
137.
QiZ.T., KalkeriG., HanibleJ., PrabhuR., BastianF., GarryR.F. & DashS. (2003). Stemloop structures II-IV of the 5’ untranslated sequences are required for the expression of the full-length hepatitis C virus genome. Archives of Virology148, 449–467.
138.
PrabhuR., JoshiV., GarryR.F., BastianF., HaqueS., RegensteinF., ThungS. & DashS. (2004). Interferon alpha-2b inhibits negativestrand RNA and protein expression from full-length HCV1a infectious clone. Experimental & Molecular Pathology76, 242–252.
139.
ChungR.T., HeW., SaquibA., ContrerasA.M., XavierR.J., ChawlaA., WangT.C. & SchmidtE.V. (2001). Hepatitis C virus replication is directly inhibited by IFN-alpha in a full-length binary expression system. Proceedings of the National Academy of Sciences of the USA98, 9847–9852.
140.
HaradaT., KimD.W., SagawaK., SuzukiT., TakahashiK., SaitoI., MatsuuraY. & MiyamuraT. (1995). Characterization of an established human hepatoma cell line constitutively expressing non-structural proteins of hepatitis C virus by transfection of viral cDNA. Journal of General Virology76, 1215–1221.
141.
HeimM.H., MoradpourD. & BlumH.E. (1999). Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway. Journal of Virology73, 8469–8475.
142.
Schmidt-MendeJ., BieckE., HugleT., PeninF., RiceC.M., BlumH.E. & MoradpourD. (2001). Determinants for membrane association of the hepatitis C virus RNA-dependent RNA polymerase. Journal of Biological Chemistry276, 44,052–44,063.
143.
WolkB., SansonnoD., KrausslichH.G., DammaccoF., RiceC.M., BlumH.E. & MoradpourD. (2000). Subcellular localization, stability, and trans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines. Journal of Virology74, 2293–2304.
144.
CooperS., EricksonA.L., AdamsE.J., KansoponJ., WeinerA.J., ChienD.Y., HoughtonM., ParhamP. & WalkerC.M. (1999). Analysis of a successful immune response against hepatitis C virus. Immunity10, 439–449.
145.
KozielM.J., DudleyD., AfdhalN., ChooQ.L., HoughtonM., RalstonR. & WalkerB.D. (1993). Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV. Journal of Virology67, 7522–7532.
146.
BronowickiJ.P., VetterD., UhlG., HudziakH., UhrlacherA., VetterJ.M. & DoffoelM. (1997). Lymphocyte reactivity to hepatitis C virus (HCV) antigens shows evidence for exposure to HCV in HCV-seronegative spouses of HCV-infected patients. Journal of Infectious Diseases176, 518–522.
147.
ScognamiglioP., AccapezzatoD., CasciaroM.A., CaccianiA., ArtiniM., BrunoG., ChircuM.L., SidneyJ., SouthwoodS., AbrignaniS., SetteA. & BarnabaV. (1999). Presence of effector CD8+ T cells in hepatitis C virus-exposed healthy seronegative donors. Journal of Immunology162, 6681–6689.
148.
TakakiA., WieseM., MaertensG., DeplaE., SeifertU., LiebetrauA., MillerJ.L., MannsM.P. & RehermannB. (2000). Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nature Medicine6, 578–582.
149.
BarrettS., RyanE. & CroweJ. (1999). Association of the HLA-DRB1*01 allele with spontaneous viral clearance in an Irish cohort infected with hepatitis C virus via contaminated anti-D immunoglobulin. Journal of Hepatology30, 979–983.
150.
ChisariF.V. (1997). Cytotoxic T cells and viral hepatitis. Journal of Clinical Investigation99, 1472–1477.
151.
GrunerN.H., GerlachT.J., JungM.C., DiepolderH.M., SchirrenC.A., SchrautW.W., HoffmannR., ZachovalR., SantantonioT., CucchiariniM., CernyA. & PapeG.R. (2000). Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. Journal of Infectious Diseases181, 1528–1536.
152.
CernyA. & ChisariF.V. (1999). Pathogenesis of chronic hepatitis C: Immunological features of hepatic injury and viral persistence. Hepatology30, 595–601.
153.
DiepolderH.M., ZachovalR., HoffmannR.M., JungM.C., GerlachT. & PapeG.R. (1996). The role of hepatitis C virus specific CD4+ T lymphocytes in acute and chronic hepatitis C. Journal of Molecular Medicine74, 583–588.
154.
LechnerF., WongD.K., DunbarP.R., ChapmanR., ChungR.T., DohrenwendP., RobbinsG., PhillipsR., KlenermanP. & WalkerB.D. (2000). Analysis of successful immune responses in persons infected with hepatitis C virus. Journal of Experimental Medicine191, 1499–1512.
155.
ThimmeR., OldachD., ChangK.M., SteigerC., RayS.C. & ChisariF.V. (2001). Determinants of viral clearance and persistence during acute hepatitis C virus infection. Journal of Experimental Medicine194, 1395–1406.
156.
WedemeyerH., HeX.S., NascimbeniM., DavisA.R., GreenbergH.B., HoofnagleJ.H., LiangT.J., AlterH. & RehermannB. (2002). Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. Journal of Immunology169, 3447–3458.
157.
BukhJ., ThimmeR., MeunierJ-C., FaulkK., SpangenbergH.C., ChangK-M., SatterfieldW., ChisariF.V. & PurcellR.H. (2008). Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain. Journal of Virology82, 8183–8195.
158.
LanfordR.E. & BiggerC. (2002). Advances in model systems for hepatitis C virus research. Virology293, 1–9.
159.
BassettS.E., GuerraB., BraskyK., MiskovskyE., HoughtonM., KlimpelG.R. & LanfordR.E. (2001). Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology33, 1479–1487.
160.
LanfordR.E., GuerraB., ChavezD., BiggerC., BraskyK.M., WangX.H., RayS.C. & ThomasD.L. (2004). Cross-genotype immunity to hepatitis C virus. Journal of Virology78, 1575–1581.
161.
KaplanD.E., SugimotoK., NewtonK., ValigaM.E., IkedaF., AytamanA., NunesF.A., LuceyM.R., VanceB.A., VonderheideR.H., ReddyK.R., McKeatingJ.A. & ChangK.M. (2007). Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology132, 654–666.
162.
von HahnT., YoonJ.C., AlterH., RiceC.M., RehermannB., BalfeP. & McKeatingJ.A. (2007). Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology132, 667–678.
163.
NeumannA.U., LamN.P., DahariH., GretchD.R., WileyT.E., LaydenT.J. & PerelsonA.S. (1998). Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science, New York282, 103–107.
164.
LamN.P., NeumannA.U., GretchD.R., WileyT.E., PerelsonA.S. & LaydenT.J. (1997). Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology26, 226–231.
165.
BiggerC.B., GuerraB., BraskyK.M., HubbardG., BeardM.R., LuxonB.A., LemonS.M. & LanfordR.E. (2004). Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. Journal of Virology78, 13,779–13,792.
166.
LanfordR.E., GuerraB., LeeH., ChavezD., BraskyK.M. & BiggerC.B. (2006). Genomic response to interferon-alpha in chimpanzees: Implications of rapid downregulation for hepatitis C kinetics. Hepatology43, 961–972.
167.
JaeckelE., CornbergM., WedemeyerH., SantantonioT., MayerJ., ZankelM., PastoreG., DietrichM., TrautweinC. & MannsM.P. (2001). Treatment of acute hepatitis C with interferon alfa-2b. New England Journal of Medicine345, 1452–1457.
168.
CastetV., FournierC., SoulierA., BrilletR., CosteJ., LarreyD., DhumeauxD., MaurelP. & PawlotskyJ.M. (2002). Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro. Journal of Virology76, 8189–8199.
169.
ShimizuY.K. & YoshikuraH. (1994). Multicycle infection of hepatitis C virus in cell culture and inhibition by alpha and beta interferons. Journal of Virology68, 8406–8408.
170.
FreseM., PietschmannT., MoradpourD., HallerO. & BartenschlagerR. (2001). Interferon-alpha inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway. Journal of General Virology82, 723–733.
171.
GuoJ.T., BichkoV.V. & SeegerC. (2001). Effect of alpha interferon on the hepatitis C virus replicon. Journal of Virology75, 8516–8523.
172.
LohmannV., KornerF., KochJ., HerianU., TheilmannL. & BartenschlagerR. (1999). Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science, New York285, 110–113.
173.
LanfordR.E., GuerraB., LeeH., AverettD.R., PfeifferB., ChavezD., NotvallL. & BiggerC. (2003). Antiviral effect and virus–host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons. Journal of Virology77, 1092–1104.
174.
BlightK.J., KolykhalovA.A. & RiceC.M. (2000). Efficient initiation of HCV RNA replication in cell culture. Science, New York290, 1972–1974.
175.
HelbigK.J., LauD.T., SemendricL., HarleyH.A. & BeardM.R. (2005). Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector. Hepatology42, 702–710.
176.
SmithM.W., YueZ.N., KorthM.J., DoH.A., BoixL., FaustoN., BruixJ., CarithersR.L.J. & KatzeM.G. (2003). Hepatitis C virus and liver disease: Global transcriptional profiling and identification of potential markers. Hepatology38, 1458–1467.
177.
JiX., CheungR., CooperS., LiQ., GreenbergH.B. & HeX.S. (2003). Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C. Hepatology37, 610–621.
178.
ChenL., BorozanI., FeldJ., SunJ., TannisL.L., ColtescuC., HeathcoteJ., EdwardsA.M. & McGilvrayI.D. (2005). Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology128, 1437–1444.
179.
MacQuillanG.C., MamotteC., ReedW.D., JeffreyG.P. & AllanJ.E. (2003). Upregulation of endogenous intrahepatic interferon stimulated genes during chronic hepatitis C virus infection. Journal of Medical Virology70, 219–227.
180.
HuangY., FeldJ.J., SappR.K., NandaS., LinJ.H., BlattL.M., FriedM.W., MurthyK. & LiangT.J. (2007). Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C. Gastroenterology132, 733–744.
181.
DerS.D., ZhouA., WilliamsB.R. & SilvermanR.H. (1998). Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proceedings of the National Academy of Sciences of the USA95, 15,623–15,628.
182.
TanH., DerrickJ., HongJ., SandaC., GrosseW.M., EdenbergH.J., TaylorM., SeiwertS. & BlattL.M. (2005). Global transcriptional profiling demonstrates the combination of type I and type II interferon enhances antiviral and immune responses at clinically relevant doses. Journal of Interferon & Cytokine Research25, 632–649.
183.
MeyerM.F., LehmannM., CornbergM., WiegJ., MannsM.P., KladeC. & WedemeyerH. (2007). Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response. Virology Journal4, 58.
184.
HassanM., SelimovicD., GhozlanH. & AbdelkaderO. (2009). Hepatitis C virus core protein triggers hepatic angiogenesis by a mechanism including multiple pathways. Hepatology49, 1469–1482.
185.
PfefferS. & BaumertT.F. (2009). Unravelling the importance of microRNAs during hepatitis C virus infection in the human liver. Journal of Hepatology51, 606–609.
186.
SmithM.W., WaltersK.A., KorthM.J., FitzgibbonM., ProllS., ThompsonJ.C., YehM.M., ShuhartM.C., FurlongJ.C., CoxP.P., ThomasD.L., PhillipsJ.D., KushnerJ.P., FaustoN., CarithersR.L.J. & KatzeM.G. (2006). Gene expression patterns that correlate with hepatitis C and early progression to fibrosis in liver transplant recipients. Gastroenterology130, 179–187.
187.
LauD.T., LuxonB.A., XiaoS.Y., BeardM.R. & LemonS.M. (2005). Intrahepatic gene expression profiles and alpha-smooth muscle actin patterns in hepatitis C virus induced fibrosis. Hepatology42, 273–281.
188.
RyderS.D., IrvingW.L., JonesD.A., NealK.R. & UnderwoodJ.C. (2004). Progression of hepatic fibrosis in patients with hepatitis C: A prospective repeat liver biopsy study. Gut53, 451–455.
189.
HuiC.K., BelayeT., MontegrandeK. & WrightT.L. (2003). A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. Journal of Hepatology38, 511–517.
190.
BoccatoS., PistisR., NoventaF., GuidoM., BenvegnuL. & AlbertiA. (2006). Fibrosis progression in initially mild chronic hepatitis C. Journal of Viral Hepatitis13, 297–302.
191.
GhanyM.G., KleinerD.E., AlterH., DooE., KhokarF., PromratK., HerionD., ParkY., LiangT.J. & HoofnagleJ.H. (2003). Progression of fibrosis in chronic hepatitis C. Gastroenterology124, 97–104.
192.
LevineR.A., SandersonS.O., Ploutz-SnyderR., MurrayF., KayE., HegartyJ., NolanN., KelleherD., McDonaldG., O'KeaneJ.C. & CroweJ. (2006). Assessment of fibrosis progression in untreated Irish women with chronic hepatitis C contracted from immunoglobulin anti-D. Clinical Gastroenterology & Hepatology4, 1271–1277.
193.
PersicoM., PersicoE., SuozzoR., ConteS., De SetaM., CoppolaL., PalmentieriB., SassoF.C. & TorellaR. (2000). Natural history of hepatitis C virus carriers with persistently normal amino-transferase levels. Gastroenterology118, 760–764.
194.
Martinot-PeignouxM., BoyerN., Cazals-HatemD., PhamB.N., GervaisA., Le BretonV., LevyS., DegottC., VallaD.C. & MarcellinP. (2001). Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. Hepatology34, 1000–1005.
195.
StevensonF.K. & RosenbergW. (2001). DNA vaccination: A potential weapon against infection and cancer. Vox Sanguinis80, 12–18.
196.
ElmowalidG.A., QiaoM., JeongS-H., BorgB.B., BaumertT.F., SappR.K., HuZ., MurthyK. & LiangT.J. (2007). Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proceedings of the National Academy of Sciences of the USA104, 8427–8432.
197.
Stoll-KellerF., BarthH., Fafi-KremerS., ZeiselM.B. & BaumertT.F. (2009). Development of hepatitis C virus vaccines: Challenges and progress. Expert Review of Vaccines8, 333–345.
198.
de BruijneJ., WeeginkC.J., JansenP.L.M. & ReesinkH.W. (2009). New developments in the antiviral treatment of hepatitis C. Vox Sanguinis97, 1–12.
199.
ChooQ.L., KuoG., RalstonR., WeinerA., ChienD., Van NestG., HanJ., BergerK., ThudiumK., KuoC., KansoponJ., McFarlandJ., TabriziA., ChingK., MossB., CumminsL.B., HoughtonM. & MuchmoreE. (1994). Vaccination of chimpanzees against infection by the hepatitis C virus. Proceedings of the National Academy of Sciences of the USA91, 1294–1298.
200.
RollierC., DeplaE., DrexhageJ.A., VerschoorE.J., VerstrepenB.E., FatmiA., BrinsterC., FournillierA., WhelanJ.A., WhelanM., JacobsD., MaertensG., InchauspéG. & HeeneyJ.L. (2004). Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response. Journal of Virology78, 187–196.
201.
JeongS.H., QiaoM., NascimbeniM., HuZ., RehermannB., MurthyK. & LiangT.J. (2004). Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates. Journal of Virology78, 6995–7003.
202.
AbrahamJ.D., HimoudiN., KienF., BerlandJ.L., CodranA., BartoschB., BaumertT., Paranhos-BaccalaG., SchusterC., InchauspéG. & KienyM.P. (2004). Comparative immunogenicity analysis of modified vaccinia Ankara vectors expressing native or modified forms of hepatitis C virus E1 and E2 glycoproteins. Vaccine22, 3917–3928.
203.
BrinsterC., ChenM., BoucreuxD., Paranhos-BaccalaG., LiljestromP., LemmonierF. & InchauspéG. (2002). Hepatitis C virus non-structural protein 3-specific cellular immune responses following single or combined immunization with DNA or recombinant Semliki Forest virus particles. Journal of General Virology83, 369–381.
204.
O'HaganD.T., SinghM., DongC., UgozzoliM., BergerK., GlazerE., SelbyM., WiningerM., NgP., CrawfordK., PaliardX., CoatesS. & HoughtonM. (2004). Cationic microparticles are a potent delivery system for a HCV DNA vaccine. Vaccine23, 672–680.
205.
WuestT., BothG.W., PrinceA.M., HofmannC. & LoserP. (2004). Recombinant ovine atadenovirus induces a strong and sustained T cell response against the hepatitis C virus NS3 antigen in mice. Vaccine22, 2717–2721.
206.
PerriS., GreerC.E., ThudiumK., DoeB., LeggH., LiuH., RomeroR.E., TangZ., BinQ., DubenskyT.W.J., VajdyM., OttenG.R. & PoloJ.M. (2003). An alphavirus replicon particle chimera derived from Venezuelan equine encephalitis and Sindbis viruses is a potent gene-based vaccine delivery vector. Journal of Virology77, 10,394–10,403.
207.
PancholiP., PerkusM., TricocheN., LiuQ. & PrinceA.M. (2003). DNA immunization with hepatitis C virus (HCV) polycistronic genes or immunization by HCV DNA priming–recombinant canarypox virus boosting induces immune responses and protection from recombinant HCV-vaccinia virus infection in HLA-A2.1-transgenic mice. Journal of Virology77, 382–390.
208.
YounJ.W., HuY.W., TricocheN., PfahlerW., ShataM.T., DreuxM., CossetF.L., FolgoriA., LeeD.H., BrotmanB. & PrinceA.M. (2008). Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with replicating recombinant vaccinia virus. Journal of Virology82, 10,896–10,905.
209.
MaX., FornsX., GutierrezR., MushahwarI.K., WuT., PayetteP.J., BukhJ., PurcellR.H. & DavisH.L. (2002). DNA-based vaccination against hepatitis C virus (HCV): Effect of expressing different forms of HCV E2 protein and use of CpG-optimized vectors in mice. Vaccine20, 3263–3271.
210.
SongM.K., LeeS.W., SuhY.S., LeeK.J. & SungY.C. (2000). Enhancement of immunoglobulin G2a and cytotoxic T-lymphocyte responses by a booster immunization with recombinant hepatitis C virus E2 protein in E2 DNA-primed mice. Journal of Virology74, 2920–2925.
211.
MatsuiM., MoriyaO. & AkatsukaT. (2003). Enhanced induction of hepatitis C virus-specific cytotoxic T lymphocytes and protective efficacy in mice by DNA vaccination followed by adenovirus boosting in combination with the interleukin-12 expression plasmid. Vaccine21, 1629–1639.
212.
MakimuraM., MiyakeS., AkinoN., TakamoriK., MatsuuraY., MiyamuraT. & SaitoI. (1996). Induction of antibodies against structural proteins of hepatitis C virus in mice using recombinant adenovirus. Vaccine14, 28–36.
213.
EnglerO.B., SchwendenerR.A., DaiW.J., WolkB., PichlerW., MoradpourD., BrunnerT. & CernyA. (2004). A liposomal peptide vaccine inducing CD8+ T cells in HLA-A2.1 transgenic mice, which recognise human cells encoding hepatitis C virus (HCV) proteins. Vaccine23, 58–68.
214.
GehringS., GregoryS.H., KuzushitaN. & WandsJ.R. (2005). Type 1 interferon augments DNA-based vaccination against hepatitis C virus core protein. Journal of Medical Virology75, 249–257.
215.
GordonE.J., BhatR., LiuQ., WangY.F., TackneyC. & PrinceA.M. (2000). Immune responses to hepatitis C virus structural and nonstructural proteins induced by plasmid DNA immunizations. Journal of Infectious Diseases181, 42–50.
216.
InchauspéG., MajorM.E., NakanoI., VitvitskiL. & TrepoC. (1997). DNA vaccination for the induction of immune responses against hepatitis C virus proteins. Vaccine15, 853–856.
217.
InchauspéG., MajorM.E., NakanoI., VivitskiL., MaisonnasM. & TrepoC. (1998). Immune responses against hepatitis C virus structural proteins following genetic immunisation. Developments in Biological Standardization92, 163–168.
218.
MajorM.E., VitvitskiL., MinkM.A., SchleefM., WhalenR.G., TrepoC. & InchauspéG. (1995). DNA-based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid. Journal of Virology69, 5798–5805.
219.
YounJ.W., ParkS.H., ChoJ.H. & SungY.C. (2003). Optimal induction of T-cell responses against hepatitis C virus E2 by antigen engineering in DNA immunization. Journal of Virology77, 11,596–11,602.
220.
ZhuL.X., LiuJ., YeY., XieY.H., KongY.Y., LiG.D. & WangY. (2004). A candidate DNA vaccine elicits HCV specific humoral and cellular immune responses. World Journal of Gastroenterology10, 2488–2492.
221.
YuH., BabiukL.A. & van Drunen Littel-van den HurkS. (2004). Priming with CpG-enriched plasmid and boosting with protein formulated with CpG oligodeoxynucleotides and Quil A induces strong cellular and humoral immune responses to hepatitis C virus NS3. Journal of General Virology85, 1533–1543.
222.
PancholiP., LiuQ., TricocheN., ZhangP., PerkusM.E. & PrinceA.M. (2000). DNA prime– canarypox boost with polycistronic hepatitis C virus (HCV) genes generates potent immune responses to HCV structural and nonstructural proteins. Journal of Infectious Diseases182, 18–27.
223.
ParkS.H., YangS.H., LeeC.G., YounJ.W., ChangJ. & SungY.C. (2003). Efficient induction of T helper 1 CD4+ T-cell responses to hepatitis C virus core and E2 by a DNA prime–adenovirus boost. Vaccine21, 4555–4564.
224.
NetterH.J., MacnaughtonT.B., WooW.P., TindleR. & GowansE.J. (2001). Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes. Journal of Virology75, 2130–2141.
LeeS.W., ChoJ.H. & SungY.C. (1998). Optimal induction of hepatitis C virus envelope-specific immunity by bicistronic plasmid DNA inoculation with the granulocyte-macrophage colony-stimulating factor gene. Journal of Virology72, 8430–8436.
227.
RollierC.S., Paranhos-BaccalaG., VerschoorE.J., VerstrepenB.E., DrexhageJ.A., FagrouchZ., BerlandJ.L., Komurian-PradelF., DuvergerB., HimoudiN., StaibC., MeyrM., WhelanM., WhelanJ.A., AdamsV.C., LarreaE., RiezuJ.I., LasarteJ.J., BartoschB., CossetF.L., SpaanW.J., DiepolderH.M., PapeG.R., SutterG., InchauspéG. & HeeneyJ.L. (2007). Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity. Hepatology45, 602–613.
228.
YounJ.W., ParkS.H., LavilletteD., CossetF.L., YangS.H., LeeC.G., JinH.T., KimC.M., ShataM.T., LeeD.H., PfahlerW., PrinceA.M. & SungY.C. (2005). Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee. Hepatology42, 1429–1436.
229.
PolakosN.K., DraneD., CoxJ., NgP., SelbyM.J., ChienD., O'HaganD.T., HoughtonM. & PaliardX. (2001). Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine. Journal of Immunology166, 3589–3598.
230.
FranzusoffA., DukeR.C., KingT.H., LuY. & RodellT.C. (2005). Yeasts encoding tumour antigens in cancer immunotherapy. Expert Opinion on Biological Therapy5, 565–575.
231.
Leroux-RoelsG., DeplaE., HulstaertF., TobbackL., DincqS., DesmetJ., DesombereI. & MaertensG. (2004). A candidate vaccine based on the hepatitis C E1 protein: Tolerability and immunogenicity in healthy volunteers. Vaccine22, 3080–3086.
232.
NevensF., RoskamsT., Van VlierbergheH., HorsmansY., SprengersD., ElewautA., DesmetV., Leroux-RoelsG., QuinauxE., DeplaE., DincqS., Vander SticheleC., MaertensG. & HulstaertF. (2003). A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology38, 1289–1296.
233.
FirbasC., JilmaB., TauberE., BuergerV., JelovcanS., LingnauK., BuschleM., FrischJ. & KladeC.S. (2006). Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: A randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine24, 4343–4353.
234.
KladeC.S., WedemeyerH., BergT., HinrichsenH., CholewinskaG., ZeuzemS., BlumH., BuschleM., JelovcanS., BuergerV., TauberE., FrischJ. & MannsM.P. (2008). Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology134, 1385–1395.
235.
SchlaphoffV., KladeC.S., JilmaB., JelovcanS.B., CornbergM., TauberE., MannsM.P. & WedemeyerH. (2007). Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients. Vaccine25, 6793–6806.
236.
YutaniS., YamadaA., YoshidaK., TakaoY., TamuraM., KomatsuN., IdeT., TanakaM., SataM. & ItohK. (2007). Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy. Vaccine25, 7429–7435.
237.
SakamotoN. & WatanabeM. (2009). New therapeutic approaches to hepatitis C virus. Journal of Gastroenterology44, 643–649.
238.
FoyE., LiK., SumpterR.J., LooY.M., JohnsonC.L., WangC., FishP.M., YoneyamaM., FujitaT., LemonS.M. & GaleM.J. (2005). Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proceedings of the National Academy of Sciences of the USA102, 2986–2991.
239.
LiK., FoyE., FerreonJ.C., NakamuraM., FerreonA.C., IkedaM., RayS.C., GaleM.J. & LemonS.M. (2005). Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proceedings of the National Academy of Sciences of the USA102, 2992–2997.
240.
LamarreD., AndersonP.C., BaileyM., BeaulieuP., BolgerG., BonneauP., BosM., CameronD.R., CartierM., CordingleyM.G., FaucherA.M., GoudreauN., KawaiS.H., KukoljG., LagaceL., LaPlanteS.R., NarjesH., PoupartM.A., RancourtJ., SentjensR.E., St GeorgeR., SimoneauB., SteinmannG., ThibeaultD., TsantrizosY.S., WeldonS.M., YongC.L. & Llinas-BrunetM. (2003). An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature, London426, 186–189.
241.
CrottaS., StillaA., WackA., D'AndreaA., NutiS., D'OroU., MoscaM., FilliponiF., BrunettoR.M., BoninoF., AbrignaniS. & ValianteN.M. (2002). Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. Journal of Experimental Medicine195, 35–41.
242.
TsengC.T. & KlimpelG.R. (2002). Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. Journal of Experimental Medicine195, 43–49.
243.
FornsX., BukhJ. & PurcellR.H. (2002). The challenge of developing a vaccine against hepatitis C virus. Journal of Hepatology37, 684–695.
244.
PestkaJ.M., ZeiselM.B., BlaserE., SchurmannP., BartoschB., CossetF.L., PatelA.H., MeiselH., BaumertJ., ViazovS., RispeterK., BlumH.E., RoggendorfM. & BaumertT.F. (2007). Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proceedings of the National Academy of Sciences of the USA104, 6025–6030.
245.
LavilletteD., MoriceY., GermanidisG., DonotP., SoulierA., PagkalosE., SakellariouG., IntratorL., BartoschB., PawlotskyJ.M. & CossetF.L. (2005). Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. Journal of Virology79, 6023–6034.
246.
HaberstrohA., SchnoberE.K., ZeiselM.B., CarollaP., BarthH., BlumH.E., CossetF.L., KoutsoudakisG., BartenschlagerR., UnionA., DeplaE., OwsiankaA., PatelA.H., SchusterC., Stoll-KellerF., DoffoelM., DreuxM. & BaumertT.F. (2008). Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion. Gastroenterology135, 1719–l1728.e1.
247.
De FrancescoR., NeddermannP., TomeiL., SteinkuhlerC., GallinariP. & FolgoriA. (2000). Biochemical and immunologic properties of the non-structural proteins of the hepatitis C virus: Implications for development of antiviral agents and vaccines. Seminars in Liver Disease20, 69–83.
248.
LindenbachB.D., EvansM.J., SyderA.J., WolkB., TellinghuisenT.L., LiuC.C., MaruyamaT., HynesR.O., BurtonD.R., McKeatingJ.A. & RiceC.M. (2005). Complete replication of hepatitis C virus in cell culture. Science, New York309, 623–626.
249.
HCV Advocate (2009). Hepatitis C Treatments in Current Clinical Development (ed. FranciscusA.), 21pp. San Francisco, CA, USA: HCV Advocate. Available at: http://www.hcvadvocate.org/hepatitis/hepC/HCVDrugs.html (Accessed 17.08.10).
250.
DavisG.L., NelsonD.R., TerraultN., PruettT.L., SchianoT.D., FletcherC.V., SapanC.V., RiserL.N., LiY., WhitleyR.J. & GnannJ.W.J. (2005). A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transplantation11, 941–949.
251.
SchianoT.D., CharltonM., YounossiZ., GalunE., PruettT., Tur-KaspaR., ErenR., DaganS., GrahamN., WilliamsP.V. & AndrewsJ. (2006). Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: Results of a phase 2 randomized study. Liver Transplantation12, 1381–1389.
252.
YuM.Y., BartoschB., ZhangP., GuoZ.P., RenziP.M., ShenL.M., GranierC., FeinstoneS.M., CossetF.L. & PurcellR.H. (2004). Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proceedings of the National Academy of Sciences of the USA101, 7705–7710.
253.
KrawczynskiK., AlterM.J., TankersleyD.L., BeachM., RobertsonB.H., LambertS., KuoG., SpelbringJ.E., MeeksE., SinhaS. & CarsonD.A. (1996). Effect of immune globulin on the prevention of experimental hepatitis C virus infection. Journal of Infectious Diseases173, 822–828.
254.
SolerM., McHutchisonJ.G., KwohT.J., DorrF.A. & PawlotskyJ.M. (2004). Virological effects of ISIS 14803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES), on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resistance in the outcome of treatment. Antiviral Therapy9, 953–968.
255.
UsmanN. & BlattL.M. (2000). Nuclease-resistant synthetic ribozymes: Developing a new class of therapeutics. Journal of Clinical Investigation106, 1197–1202.
256.
ClinicalTrials.gov (2009). Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients. Bethesda, MD, USA: US National Library of Medicine. Available at: http://clinicaltrials.gov/ct2/show/NCT00255177?term=VGX&rank=4 (Accessed 17.08.10).
257.
ClinicalTrials.gov (2008). A Study to Evaluate the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C. Bethesda, MD, USA: US National Library of Medicine. Available at: http://clinicaltrials.gov/ct2/show/NCT00332176?term=celgosivir&rank=1 (Accessed 17.08.10).
258.
Del VecchioA.M. & SariskyR.T. (2006). Small molecule and biologic inhibitors of hepatitis C virus: A symbiotic approach. Mini Reviews in Medicinal Chemistry6, 1263–1268.
259.
MoH., LuL., Pilot-MatiasT., PithawallaR., MondalR., MasseS., DekhtyarT., NgT., KoevG., StollV., StewartK.D., PrattJ., DonnerP., RockwayT., MaringC. & MollaA. (2005). Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro. Antimicrobial Agents & Chemotherapy49, 4305–4314.
260.
LuL., DekhtyarT., MasseS., PithawallaR., KrishnanP., HeW., NgT., KoevG., StewartK., LarsonD., BosseT., WagnerR., Pilot-MatiasT., MoH. & MollaA. (2007). Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro. Antiviral Research76, 93–97.
261.
ChenC.M., HeY., LuL., LimH.B., TripathiR.L., MiddletonT., HernandezL.E., BenoD.W., LongM.A., KatiW.M., BosseT.D., LarsonD.P., WagnerR., LanfordR.E., KohlbrennerW.E., KempfD.J., Pilot-MatiasT.J. & MollaA. (2007). Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model. Antimicrobial Agents & Chemotherapy51, 4290–4296.
262.
KronenbergerB. & ZeuzemS. (2008). Future treatment options for HCV: Double, triple, what is the optimal combination?Best Practice & Research Clinical Gastroenterology22, 1123–1136.
263.
CoelmontL., PaeshuyseJ., WindischM.P., De ClercqE., BartenschlagerR. & NeytsJ. (2006). Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2'-C-methylcytidine, the active component of valopicitabine. Antimicrobial Agents & Chemotherapy50, 3444–3446.
264.
SorianoV., PetersM.G. & ZeuzemS. (2009). New therapies for hepatitis C virus infection. Clinical Infectious Diseases48, 313–320.
265.
YaoN., HessonT., CableM., HongZ., KwongA.D., LeH.V. & WeberP.C. (1997). Structure of the hepatitis C virus RNA helicase domain. Nature Structural Biology4, 463–467.
266.
KimJ.L., MorgensternK.A., LinC., FoxT., DwyerM.D., LandroJ.A., ChambersS.P., MarklandW., LepreC.A., O'MalleyE.T., HarbesonS.L., RiceC.M., MurckoM.A., CaronP.R. & ThomsonJ.A. (1996). Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell87, 343–355.
267.
LinC., KwongA.D. & PerniR.B. (2006). Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infectious Disorders Drug Targets6, 3–16.
268.
LinK., PerniR.B., KwongA.D. & LinC. (2006). VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells. Antimicrobial Agents & Chemotherapy50, 1813–1822.
269.
MalcolmB.A., LiuR., LahserF., AgrawalS., BelangerB., ButkiewiczN., ChaseR., GheyasF., HartA., HeskD., IngravalloP., JiangC., KongR., LuJ., PichardoJ., ProngayA., SkeltonA., TongX., VenkatramanS., XiaE., GirijavallabhanV. & NjorogeF.G. (2006). SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrobial Agents & Chemotherapy50, 1013–1020.
270.
NeukamK., MacíasJ., MiraJ.A. & PinedaJ.A. (2009). A review of current anti-HCV treatment regimens and possible future strategies. Expert Opinion on Pharmacotherapy10, 417–433.
271.
LinC., LinK., LuongY.P., RaoB.G., WeiY.Y., BrennanD.L., FulghumJ.R., HsiaoH.M., MaS., MaxwellJ.P., CottrellK.M., PerniR.B., GatesC.A. & KwongA.D. (2004). In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: Structural analysis indicates different resistance mechanisms. Journal of Biological Chemistry279, 17,508–17,514.
272.
HinrichsenH., BenhamouY., WedemeyerH., ReiserM., SentjensR.E., CallejaJ.L., FornsX., ErhardtA., CronleinJ., ChavesR.L., YongC.L., NehmizG. & SteinmannG.G. (2004). Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology127, 1347–1355.
273.
WatashiK., IshiiN., HijikataM., InoueD., MurataT., MiyanariY. & ShimotohnoK. (2005). Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Molecular Cell19, 111–122.
274.
FlisiakR., HorbanA., GallayP., BobardtM., SelvarajahS., Wiercinska-DrapaloA., SiwakE., CielniakI., HigersbergerJ., KierkusJ., AeschlimannC., GrosgurinP., Nicolas-MetralV., DumontJ.M., PorchetH., CrabbeR. & ScalfaroP. (2008). The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology47, 817–826.
275.
CrabbéR., VuagniauxG., DumontJ-M., Nicolas-MétralV., MarfurtJ. & NovaroliL. (2009). An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C. Expert Opinion on Investigational Drugs18, 211–220.
276.
PaeshuyseJ., KaulA., De ClercqE., RosenwirthB., DumontJ.M., ScalfaroP., BartenschlagerR. & NeytsJ. (2006). The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology43, 761–770.
277.
RossignolJ.F., ElfertA., El-GoharyY. & KeeffeE.B. (2009). Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology136, 856–862.
278.
De LeedeL.G., HumphriesJ.E., BechetA.C., Van HoogdalemE.J., VerrijkR. & SpencerD.G. (2008). Novel controlled-release Lemna-derived IFN-alpha2b (Locteron): Pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial. Journal of Interferon & Cytokine Research28, 113–122.
279.
RustgiV.K. (2009). Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C. Current Medical Research & Opinion25, 991–1002.
280.
HorsmansY., BergT., DesagerJ.P., MuellerT., SchottE., FletcherS.P., SteffyK.R., BaumanL.A., KerrB.M. & AverettD.R. (2005). Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology42, 724–731.
281.
McHutchisonJ.G., BaconB.R., GordonS.C., LawitzE., ShiffmanM., AfdhalN.H., JacobsonI.M., MuirA., Al-AdhamiM., MorrisM.L., Lekstrom-HimesJ.A., EflerS.M. & DavisH.L. (2007). Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology46, 1341–1349.
282.
GishR.G., AroraS., Rajender ReddyK., NelsonD.R., O'BrienC., XuY. & MurphyB. (2007). Virological response and safety outcomes in therapy-naïve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: A randomized, phase 2 study. Journal of Hepatology47, 51–59.
283.
HirataY., SudohM. & KoharaM. (2008). Suppression of hepatitis C virus with the reagent targetting host factors. [In Japanese] Uirusu58, 207–213.
284.
KrawczykM., Wasowska-LukawskaM., OszczapowiczI. & Boguszewska-ChachulskaA.M. (2009). Amidinoanthracyclines — a new group of potential anti-hepatitis C virus compounds. Biological Chemistry390, 351–360.
285.
PawlotskyJ.M. & McHutchisonJ.G. (2004). Hepatitis C. Development of new drugs and clinical trials: Promises and pitfalls. Summary of an AASLD hepatitis single topic conference. Hepatology39, 554–567.
286.
StandringD.N., LanfordR., WrightT., ChungR.T., BichkoV., Cretton-ScottE., Pan-ZhouX., BergelsonS., QuL., TausekM., BridgesE., MoussaA., StorerR., PierraC., BenzariaS., GosselinG., La CollaP. & SommadossiJ.P. (2003). NM 283 has potent antiviral activity against genotype 1 chronic hepatitis C virus (HCV-1) infection in the chimpanzee. Journal of Hepatology38, 3–64.
StandringD.N., LanfordR., LiB., PanzoR.J., SeiferM., LarssonM., GoodS.S. & ZhouX.J. (2009). Antiviral Activity of the Liver-Targeted Nucleotide HCV Polymerase Inhibitor IDX184 Correlates with Trough Serum Levels of the Nucleoside Metabolite in HCV-infected Chimpanzees. New York, NY, USA: National AIDS Treatment Advocacy Project. Available at: http://www.natap.org/2009/EASL/EASL_63.htm (Accessed 17.08.10).
290.
OlsenD.B., CarrollS.S., HandtL., LudmererS., GrahamD., FandozziC., DeLucaL., LivertonN., VaccaJ. & HazudaD. (2009). HCV Antiviral Activity and Resistance Analysis in Chronically Infected Chimpanzees Treated with Merck NS3/4A Protease and NS5B Polymerase Inhibitors. New York, NY, USA: National AIDS Treatment Advocacy Project. Available at: http://www.natap.org/2007/EASL/EASL_59.htm (Accessed 17.08.10).
291.
OlsenD.B., CarrollS.S., HandtL., LudmererS., GrahamD., FandozziC., DeLucaL., LivertonN., VaccaJ. & HazudaD. (2009). Merck HCV Protease & Polymerase Inhibitor Viral Load Reduction & Resistance in Chimps. New York, NY, USA: National AIDS Treatment Advocacy Project. Available at: http://www.natap.org/2007/EASL/EASL_14.htm (Accessed 17.08.10).
292.
Anon. (2009). The Nucleoside Inhibitor MK-0608 Mediates Suppression of HCV Replication for >30 Days in Chronically Infected Chimpanzees. New York, NY, USA: National AIDS Treatment Advocacy Project. Available at: http://www.natap.org/2006/ICAAC/ICAAC_13.htm (Accessed 17.08.10).
293.
Southwest Foundation for Biomedical Research (2009). New drug technology produces marked improvement in hepatitis C therapy in animals; may be useful for a wide range of diseases. San Antonio, TX, USA: Southwest Foundation for Biomedical Research. Available at: http://www.sfbr.org/News/detail.aspx?id=167 (Accessed 17.08.10).
294.
LanfordR.E., Hildebrandt-EriksenE.S., PetriA., PerssonR., LindowM., MunkM.E., KauppinenS. & OrumH. (2009). Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science, New York327, 198–201.
295.
RyderN.S. (2007). Discontinued drugs in 2006: Anti-infectives. Expert Opinion on Investigational Drugs16, 1867–1878.
296.
RyderN.S. (2009). Discontinued drugs in 2007: Anti-infectives. Expert Opinion on Investigational Drugs18, 1–11.
297.
RyderN.S. (2010). Discontinued drugs in 2008: Anti-infectives. Expert Opinion on Investigational Drugs19, 1–21.
298.
Brown-AugsburgerP., YueX.M., LockridgeJ.A., McSwiggenJ.A., KambojD. & HillgrenK.M. (2004). Development and validation of a sensitive, specific, and rapid hybridization-ELISA assay for determination of concentrations of a ribozyme in biological matrices. Journal of Pharmaceutical & Biomedical Analysis34, 129–139.
299.
Gonzalez-AseguinolazaG., CrettazJ., OchoaL., OtanoI., AldabeR. & PanedaA. (2006). Gene therapy for viral hepatitis. Expert Opinion on Biological Therapy6, 1263–1278.
MeulemanP. & Leroux-RoelsG. (2008). The human liver-uPA-SCID mouse: A model for the evaluation of antiviral compounds against HBV and HCV. Antiviral Research80, 231–238.
302.
MercerD.F., SchillerD.E., ElliottJ.F., DouglasD.N., HaoC., RinfretA., AddisonW.R., FischerK.P., ChurchillT.A., LakeyJ.R., TyrrellD.L. & KnetemanN.M. (2001). Hepatitis C virus replication in mice with chimeric human livers. Nature Medicine7, 927–933.
303.
MeulemanP., LibbrechtL., De VosR., de HemptinneB., GevaertK., VandekerckhoveJ., RoskamsT. & Leroux-RoelsG. (2005). Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology41, 847–856.
304.
JoplingC.L., YiM., LancasterA.M., LemonS.M. & SarnowP. (2005). Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science, New York309, 1577–1581.
305.
JoplingC.L., NormanK.L. & SarnowP. (2006). Positive and negative modulation of viral and cellular mRNAs by liver-specific microRNA miR-122. Cold Spring Harbor Symposia on Quantitative Biology71, 369–376.
ElmenJ., LindowM., SilahtarogluA., BakM., ChristensenM., Lind-ThomsenA., HedtjarnM., HansenJ.B., HansenH.F., StraarupE.M., McCullaghK., KearneyP. & KauppinenS. (2008). Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Research36, 1153–1162.
310.
KatoT., MatsumuraT., HellerT., SaitoS., SappR.K., MurthyK., WakitaT. & LiangT.J. (2007). Production of infectious hepatitis C virus of various genotypes in cell cultures. Journal of Virology81, 4405–4411.
311.
WakitaT., PietschmannT., KatoT., DateT., MiyamotoM., ZhaoZ., MurthyK., HabermannA., KräusslichH.G., MizokamiM., BartenschlagerR. & LiangT.J. (2005). Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nature Medicine11, 791–796.
312.
RosenH.R. & MartinP. (2000). Hepatitis B and C in the liver transplant recipient. Seminars in Liver Disease20, 465–480.
313.
BaileyJ. (2005). Non-human primates in medical research and drug development: A critical review. Biogenic Amines19, 235–256.
314.
CombesR.D., BerridgeT., ConnellyJ., EveM.D., GarnerR.C., ToonS. & WilcoxP. (2003). Early microdose drug studies in human volunteers can minimise animal testing: Proceedings of a workshop organised by Volunteers in Research and Testing. European Journal of Pharmaceutical Sciences19, 1–11.
KremsdorfD. & BrezillonN. (2007). New animal models for hepatitis C viral infection and pathogenesis studies. World Journal of Gastroenterology13, 2427–2435.
317.
WuG.Y., KonishiM., WaltonC.M., OliveD., HayashiK. & WuC.H. (2005). A novel immuno-competent rat model of HCV infection and hepatitis. Gastroenterology128, 1416–1423.
318.
IlanE., AraziJ., NussbaumO., ZaubermanA., ErenR., LubinI., NevilleL., Ben-MosheO., KischitzkyA., LitchiA., MargalitI., GopherJ., MounirS., CaiW., DaudiN., EidA., JurimO., CzerniakA., GalunE. & DaganS. (2002). The hepatitis C virus (HCV)-Trimera mouse: A model for evaluation of agents against HCV. Journal of Infectious Diseases185, 153–161.
319.
IlanE., ErenR., LubinI., NussbaumO., ZaubermanA. & DaganS. (2002). The Trimera mouse: A system for generating human monoclonal antibodies and modeling human diseases. Current Opinion in Molecular Therapeutics4, 102–109.
MoriyaK., FujieH., ShintaniY., YotsuyanagiH., TsutsumiT., IshibashiK., MatsuuraY., KimuraS., MiyamuraT. & KoikeK. (1998). The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nature Medicine4, 1065–1067.
322.
BukhJ., EngleR.E., GovindarajanS. & PurcellR.H. (2008). Immunity against the GBV-B hepatitis virus in tamarins can prevent productive infection following rechallenge and is long-lived. Journal of Medical Virology80, 87–94.
323.
WoollardD.J., HaqshenasG., DongX., PrattB.F., KentS.J. & GowansE.J. (2008). Virus-specific T-cell immunity correlates with control of GB virus B infection in marmosets. Journal of Virology82, 3054–3060.
324.
NamJ.H., FaulkK., EngleR.E., GovindarajanS., St ClaireM. & BukhJ. (2004). In vivo analysis of the 3’ untranslated region of GB virus B after in vitro mutagenesis of an infectious cDNA clone: Persistent infection in a transfected tamarin. Journal of Virology78, 9389–9399.
325.
LanfordR.E., ChavezD., NotvallL. & BraskyK.M. (2003). Comparison of tamarins and marmosets as hosts for GBV-B infections and the effect of immunosuppression on duration of viremia. Virology311, 72–80.
326.
XieZ.C., Riezu-BojJ.I., LasarteJ.J., GuillenJ., SuJ.H., CiveiraM.P. & PrietoJ. (1998). Transmission of hepatitis C virus infection to tree shrews. Virology244, 513–520.
327.
US Government Printing Office (2007). Transportation, sale, and handling of certain animals. In Animal Welfare Act as Amended, pp. 2131–2159. Washington, DC, USA: Government Printing Office. Available at: http://frwebgate.access.gpo.gov/cgi-bin/usc.cgi?ACTION=BROWSE&TITLE=7USCC54 (Accessed 17.08.10).
FornsX., PayetteP.J., MaX., SatterfieldW., EderG., MushahwarI.K., GovindarajanS., DavisH.L., EmersonS.U., PurcellR.H. & BukhJ. (2000). Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. Hepatology32, 618–625.
330.
CaponeS., ZampaglioneI., VitelliA., PezzaneraM., KiersteadL., BurnsJ., RuggeriL., ArcuriM., CappellettiM., MeolaA., ErcoleB.B., TafiR., SantiniC., LuzzagoA., FuT-M., CollocaS., CilibertoG., CorteseR., NicosiaA., FattoriE. & FolgoriA. (2006). Modulation of the immune response induced by gene electrotransfer of a hepatitis C virus DNA vaccine in nonhuman primates. Journal of Immunology177, 7462–7471.
